Export as PDF
Cohort Acronym

Cohort type
Neurodegenerative disease-specific cohort

Parkinson's disease

Participant type
At-risk diagnosis, Condition diagnosed, No diagnosis

Recruitment Period 2011-2015 
Sample size at start or planned sample size if still recruiting  
Estimated Current Sample Size  
Age at Recruitment    
Gender Male and Female 

The LRRK2 Cohort Consortium (LCC) comprises three closed studies: the LRRK2 Cross-sectional Study, LRRK2 Longitudinal Study and the 23andMe Blood Collection Study. The LCC followed standardized data acquisition protocols, and clinical data and biological samples are stored in a comprehensive Parkinson’s database and biorepository, respectively. A total of 1,213 Idiopathic PD subjects, 1,168 PD subjects with genetic mutations in LRRK2, 1,123 unaffected subjects with genetic mutations in LRRK2, and 779 Healthy Controls (HC) were recruited.

Country Canada, China, France, Germany, Israel, Norway, Spain, Tunisia, USA 
Contact details
Institution name The Michael J. Fox Foundation for Parkinson's Research 
Website https://www.michaeljfox.org/page.html?lrrk2-cohort-consortium&navid=lrrk2-cohort-consortium 
Principal Investiator (PI)  
Contact email [email protected] 
Contact phone number 212-509-0995 
Funders (Core support) The Michael J. Fox Foundation for Parkinson’s Research 

Variables Collected

Brain related measures: N/A
Funtional rating: Individual physiological, Individual psychological
Anthropometric: Blood pressure
Physical: Cardiovascular, Musculoskeletal, Reproductive, Respiratory
Biological samples: Blood, Cerebral spinal fluid (CSF), Other, Urine
Genotyping: Gene screening
Brain imaging: Magnetic resonance imaging (MRI), Positron emission tomography (PET) fluorine18 flurodeoxyglucose (FDG), Single photon emission computerised tomography (SPECT)
Brain banking: N/A
Lifestyle: Alcohol, Dietary habits, Physical activity, Smoking
Socio-economic: Education, Ethnic group, Family circumstances
Health service utilisation: N/A
Export as PDF